Clinical Trials
31 trialsEMEG-ECDD
Centre Georges Francois Leclerc
REaCT-OGF
Ottawa Hospital Research Institute
SATROPIN
MedSIR
PRIMED
MedSIR
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
EMEG-E-01
Centre Georges Francois Leclerc
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
M.D. Anderson Cancer Center
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Dartmouth-Hitchcock Medical Center
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
University of Washington
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Stanford University
OTT14-03
Ottawa Hospital Research Institute
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
University of Washington
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
National Cancer Institute (NCI)
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
University of Washington
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Hellenic Oncology Research Group
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
National Cancer Institute (NCI)
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
Hellenic Oncology Research Group
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
SWOG Cancer Research Network
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
Case Comprehensive Cancer Center
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12
University of Washington
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer
M.D. Anderson Cancer Center
The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC
ChineseAMS
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
National Institutes of Health Clinical Center (CC)
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Hellenic Oncology Research Group
Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer
University of Washington